Baseline prevalence of polypharmacy in older hypertensive study subjects with elevated dementia risk: Findings from the risk reduction for Alzheimer’s disease study (rrAD)

Manuscript Number: 

20-0122R2

Author(s): 
Ellen F. Binder, Jeffrey M. Burns, C. Munro Cullum, William P. Gahan, Linda S. Hynan, Ashwini Kamat, Jeffrey N. Keller, Diana R. Kerwin, Victoria Ourso, Eric Vidoni, Wanpen Vongpatanasin, Kaylee Woodard, Rong Zhang, David C. Zhu

Disclosures

Ellen F. Binder

  • Nothing to Disclose

Jeffrey M. Burns

  • Grants
    • Agency: 
      Avid Radiopharmaceuticals
      Dates: 
      2014 to current
    • Agency: 
      Astra Zeneca
      Dates: 
      2018 to current

C. Munro Cullum

  • Nothing to Disclose

William P. Gahan

  • Nothing to Disclose

Linda S. Hynan

  • Nothing to Disclose

Ashwini Kamat

  • Nothing to Disclose

Jeffrey N. Keller

  • Nothing to Disclose

Diana R. Kerwin

  • Consulting Fees:
    Advisory Board for Eisai, honorarium and travel expense reimbursement for meeting attendance only
    Equity:
    Stock options owned in a privately traded company that is not associated with any aspect of this paper content or medications discussed.

Victoria Ourso

  • Nothing to Disclose

Eric Vidoni

  • Patents/Royalties
    I am co-named on a provisional patent that is unrelated to this manuscript.

Wanpen Vongpatanasin

  • Nothing to Disclose

Kaylee Woodard

  • Nothing to Disclose

Rong Zhang

  • Nothing to Disclose

David C. Zhu

  • Nothing to Disclose